#site agnostic

Targeted therapy demonstrated high response rates for thyroid tumors with RET mutations or fusions.

The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.

A retrospective analysis showed that 29% of people with previously treated tumors responded to treatment.

Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.

TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.

New site-agnostic therapies highlight the importance of genetic testing.

Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.

FDA approves Rozlytrek for cancers with certain gene mutations

Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.

New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.

RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.

All 12 treated children with NTRK, ROS1 or ALK gene abnormalities showed partial or compete tumor shrinkage.

Researchers continue to develop new drugs that target cancer with specific genetic mutations anywhere in the body.